<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455935</url>
  </required_header>
  <id_info>
    <org_study_id>NEU 3200411A</org_study_id>
    <nct_id>NCT01455935</nct_id>
  </id_info>
  <brief_title>Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention</brief_title>
  <acronym>WASSABI</acronym>
  <official_title>Wake up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobs Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University at Buffalo Neurosurgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jacobs Neurological Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to study the safety and the effectiveness of using CT Perfusion&#xD;
      studies as an indicator to treat stroke patients with unknown time of onset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale (mRS) 90 days post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>24 hour</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) 24 hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>3-29 day</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) at discharge (3-29 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>30 post treatment</time_frame>
    <description>Modified Rankin Scale (mRS) at 30 days post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow</measure>
    <time_frame>Pre - up to1 hour prior to procedure and post will be up to1 hour after completion of procedure</time_frame>
    <description>Thrombolysis In Myocardial Infarction (TIMI) flow pre and post the intervention as an indicator of revascularization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thomboylsis in Cerebral Ischemia (TICI) flow</measure>
    <time_frame>Pre - will be no more than 1 hour prior to procedure and post will be no more then 1 hour after completion of procedure</time_frame>
    <description>Thomboylsis in Cerebral Ischemia (TICI) flow pre and post intervention as an indicator of revascularization rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic intracranial Hemorrhage (ICH)</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of symptomatic symptomatic intracranial Hemorrhage (ICH) within 72 hours of intervention defined by ECASSIII as 4 points worsening in NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>30 Days</time_frame>
    <description>at 30 Day visit National Institute of Health Stroke Scale (NIHSS) will be assessed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current standard of care per the latest stroke guidelines&#xD;
Permissive Hypertension up to 220&#xD;
Antipletelets therapy:&#xD;
ASA 81 mg PO daily or&#xD;
Plavix 75 mg PO daily or&#xD;
Aggrenox 225mg PO twice daily&#xD;
Anti-inflammatory therapy:&#xD;
Lipitor 80 mg PO daily or&#xD;
Crestor 20 mg PO daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full dose Intravenous thrombolysis&#xD;
0.9 mg/kg&#xD;
Maximum dose is 90 mg&#xD;
10% of the dose will be given over one minute&#xD;
90% of the dose will be infused over 1 hour&#xD;
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications&#xD;
Neuro checks every 5 minutes during the infusion&#xD;
Neuro checks every hour after the infusion for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-Arterial Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Choice of therapy per experienced Endovascular surgeon and includes:&#xD;
Intra arterial Activase (Maximum dose of 22 mg)&#xD;
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)&#xD;
PENUMBRA device (no standard time frame for how long the procedure takes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-platelets and statin</intervention_name>
    <arm_group_label>Medical Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <description>Full dose Intravenous thrombolysis&#xD;
0.9 mg/kg&#xD;
Maximum dose is 90 mg&#xD;
10% of the dose will be given over one minute&#xD;
90% of the dose will be infused over 1 hour&#xD;
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications&#xD;
Neuro checks every 5 minutes during the infusion&#xD;
Neuro checks every hour after the infusion for 24 hours</description>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intra arterial intervention</intervention_name>
    <description>Intra arterial Activase (Maximum dose of 22 mg)&#xD;
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)&#xD;
PENUMBRA device (no standard time frame for how long the procedure takes)</description>
    <arm_group_label>Intra-Arterial Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria: To be eligible for entry into this study, candidates must meet all of&#xD;
        the following eligibility criteria at the time of Emergency Department presentation:&#xD;
&#xD;
          1. Age: 18-80 years old&#xD;
&#xD;
          2. Ischemic Wake Up Stroke (Unknown time of onset but less than 24 hours since last seen&#xD;
             normal)&#xD;
&#xD;
          3. National Institute of Health Stroke Scale (NIHSS) 8-22&#xD;
&#xD;
          4. Evidence of penumbra on Computed Tomography Perfusion(CTP) as mentioned above&#xD;
&#xD;
          5. Alberta Stroke Program Early Computed Tomography (CT) Score (ASPECTS 7 or more)&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria: Potential study patients will be excluded from study entry if any of&#xD;
        the following exclusion criteria exist at the time of screening:&#xD;
&#xD;
          1. Evidence of intracranial hemorrhage (Intracerebral hematoma, intraventricular&#xD;
             hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic&#xD;
             subdural hematoma (SDH)) on the baseline CT&#xD;
&#xD;
          2. Historical Modified Rankin Scale (mRS) of â‰¥2&#xD;
&#xD;
          3. National Institute of Health Stroke Scale (NIHSS)&lt;8 at the time of treatment&#xD;
&#xD;
          4. Positive pregnancy test in women at age of childbearing&#xD;
&#xD;
          5. Intracranial or intraspinal surgery within 3 months&#xD;
&#xD;
          6. Stroke or serious head injury within 3 months&#xD;
&#xD;
          7. History of intracranial hemorrhage&#xD;
&#xD;
          8. Uncontrolled hypertension at time of treatment (eg, &gt;185 mm Hg systolic or &gt;110 mm Hg&#xD;
             diastolic)&#xD;
&#xD;
          9. Seizure at the onset of stroke&#xD;
&#xD;
         10. Active internal bleeding&#xD;
&#xD;
         11. Intracranial neoplasm&#xD;
&#xD;
         12. Arteriovenous malformation or aneurysm&#xD;
&#xD;
         13. Clinical presentation suggesting post-MI pericarditis&#xD;
&#xD;
         14. Known bleeding diathesis including but not limited to current use of oral&#xD;
             anticoagulants producing an Internation normalized ratio (INR) &gt;1.7&#xD;
&#xD;
         15. Internation normalized ratio (INR) &gt;1.7&#xD;
&#xD;
         16. Administration of heparin within 48 hours preceding the onset of stroke with an&#xD;
             elevated activated Partial Thromboplastin Time(aPTT) at presentation&#xD;
&#xD;
         17. Platelet count &lt;100,000/mm&#xD;
&#xD;
         18. Major surgery within 2 weeks&#xD;
&#xD;
         19. GastroIntestinal (GI) or urinary tract hemorrhage within 3 weeks&#xD;
&#xD;
         20. Aggressive treatment required to lower blood pressure&#xD;
&#xD;
         21. Glucose level &lt;50 or &gt;400 mg/dL&#xD;
&#xD;
         22. Arterial puncture at a noncompressible site or lumbar puncture within 1 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elad I Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>University at Buffalo Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tareq Kass-Hout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobs Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tareq Kass-Hout, MD</last_name>
    <phone>716-887-5548</phone>
    <email>kasshouttareq@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Millard Fillmore Gates Circle Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie Crumlish</last_name>
      <phone>716-887-5548</phone>
      <email>acrumlish@thejni.org</email>
    </contact>
    <investigator>
      <last_name>Tareq Kass-Hout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elad Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adnan H Siddiqui, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth V Snyder, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>L N Hopkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert N Sawyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilou Ching, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Janicke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jacobs Neurological Institute</investigator_affiliation>
    <investigator_full_name>Tareq Kass-Hout</investigator_full_name>
    <investigator_title>Chief Vascular/Neurology Resident in charge of stroke</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

